ESR1 gene amplification in endometrial carcinomas: A clinicopathological analysis

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3775-3782

  Rahman, Mohammed Tanjimur ^a   Nakayama, Kentaro ^a   Rahman, Munmun ^a   Ishikawa, Masako ^a   Katagiri, Hiroshi ^a   Katagiri, Atsuko ^a   Ishibashi, Tomoka ^a   Sato, Emi ^a   Iida, Kouji ^a   Ishikawa, Noriyuki ^a   Nakayama, Naomi ^a   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Endometrial carcinoma; ER PR; ESR1; Gene amplification

Indexed keywords

ARID1A PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN MLH1; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; ENDOMETRIUM CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENCE MICROSCOPY; FOLLOW UP; GENE AMPLIFICATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR INVASION;

ENDOMETRIAL CARCINOMA; ER/PR; ESR1; GENE AMPLIFICATION;

ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 84884996154     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Akhmedkhanov A, Zeleniuch-Jacquotte A and Toniolo P: Role of exogenous and endogenous hormones in endometrial cancer: Review of the evidence and research perspectives. Ann NY Acad Sci 943: 296-315, 2001.
3. Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P and Prat J: Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32: 569-577, 2001.
4. Shiozawa T and Konishi I: Early endometrial carcinoma: Clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment. Int J Clin Oncol 11: 13-21, 2006.
5. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R and Ellenson LH: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935-3940, 1997.
6. Oda K, Stokoe D, Taketani Y and McCormick F: High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65: 10669-10673, 2005.
7. Debies MT and Welch DR: Genetic basis of human breast cancer metastasis. J Mammary Gland Biol Neoplasia 6: 441-451, 2001.
8. Albertson DG, Collins C, McCormick F and Gray JW: Chromosome aberrations in solid tumors. Nat Genet 34: 369-376, 2003.
9. Wang TL, Diaz LA Jr, Romans K, Bardelli A, Saha S Galizia G, Choti M, Donehower R, Parmigiani G, Shih Ie M, Iacobuzio-Donahue C, Kinzler KW, Vogelstein B, Lengauer C and Velculescu VE: Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA 101: 3089-3094, 2004.
10. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Janicke F, Sauter G and Simon R: Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39: 655-660, 2007.
11. Moelans CB, Monsuur HN, de Pinth JH, Radersma RD, de Weger RA and van Diest PJ: ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: A multiplex ligation-dependent probe amplification study. Cell Oncol 34: 489-494, 2011.
12. Laenkholm AV, Knoop A, Ejlertsen B, Rudbeck T, Jensen MB, Muller S, Lykkesfeldt AE, Rasmussen BB and Nielsen KV: ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry. Mol Oncol 6: 428-436, 2012.
13. Nielsen KV, Ejlertsen B, Muller S, Moller S, Rasmussen BB, Balslev E, Laenkholm AV, Christiansen P and Mouridsen HT: Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat 127: 345-355, 2011.
14. Lebeau A, Grob T, Holst F, Seyedi-Fazlollahi N, Moch H, Terracciano L, Turzynski A, Choschzick M, Sauter G and Simon R: Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. J Pathol 216: 151-157, 2008.
15. Skaland I, Ovestad I, Janssen EA, Klos J, Kjellevold KH, Helliesen T and Baak JP: Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer. J Clin Pathol 61: 68-71, 2008.
16. Rahman M, Nakayama K, Rahman MT, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K and Miyazaki K: Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer. Hum Pathol 44: 103-109, 2013.
17. Rahman MT, Nakayama K, Ishikawa M, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Iida K and Miyazaki K: Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer. Oncology 84: 166-173, 2013.
18. Nyholm HC, Christensen IJ and Nielsen AL: Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Gynecol Oncol 59: 347-351, 1995.
19. Creasman WT: Prognostic significance of hormone receptors in endometrial cancer. Cancer 71: 1467-1470, 1993.
20. Kadar N, Malfetano JH and Homesley HD: Steroid receptor concentrations in endometrial carcinoma: Effect on survival in surgically staged patients. Gynecol Oncol 50: 281-286, 1993.
21. Carcangiu ML, Chambers JT, Voynick IM, Pirro M and Schwartz PE: Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma Part I: Clinical and histologic correlations. Am J Clin Pathol 94: 247-254, 1990.
22. Okuda T, Sekizawa A, Purwosunu Y, Nagatsuka M, Morioka M, Hayashi M and Okai T: Genetics of endometrial cancers. Obstet Gynecol Int 2010: 984013, 2010.
23. Llobet D, Pallares J, Yeramian A, Santacana M, Eritja N, Velasco A, Dolcet X and Matias-Guiu X: Molecular pathology of endometrial carcinoma: Practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol 62: 777-785, 2009.
24. Ioffe OB, Papadimitriou JC and Drachenberg CB: Correlation of proliferation indices, apoptosis, and related oncogene expression (BCL2 and c-ERBB2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 29: 1150-1159, 1998.
25. Sherman ME, Bur ME and Kurman RJ: p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis. Hum Pathol 26: 1268-1274, 1995.